Barclays says there will be no job cuts, even as insiders brace for the worst and an activist ratchets up pressure to gut the investment bank

Trista Kelley,Alex Morrell | Senior Barclays staff have been bracing for staff and bonus reductions following the departure of key investment banking bosses.

Read More »

Hedge fund titan Crispin Odey had a huge short bet on Wirecard — and may have been hammered by the stock's surge after SoftBank's investment

Callum Burroughs | Odey Asset Management, led by the Brexit-supporting UK hedge fund titan Crispin Odey, may have lost millions of euros shorting Wirecard's stock.

Read More »

One of America’s top-ranked advisers for the ultrarich is making a surprising investment choice in preparation for the next recession

Marley Jay | Brian Pfeifler of Morgan Stanley says recessions are big opportunities for some companies, and investors shouldn't be too afraid of those downturns.

Read More »

A fund manager dominating 95% of his competitors reveals the stock picks that have given him the biggest boost — and shares his big bet for the future

Joe Ciolli | Gerry Frigon, one of the market's top-performing stock pickers, shares the novel investing strategy he's relying on for future returns.

Read More »

Inside Amazon's charm offensive to win over big brand budgets from Madison Avenue

Lauren Johnson | Amazon is trying to build its relationship with big agencies to show that its platform can do more than drive sales.

Read More »

The Trump administration just gave a big boost to a new kind of doctor's office that charges monthly fees and could be the future of medicine

Lydia Ramsey | CMS plans to pay some doctors on a monthly basis to care for Medicare patients, a "profound change" for the US health program for the elderly.

Read More »

Advertisers have long considered Snap to be an experimental buy. Fresh data suggests that's beginning to change.

Tanya Dua | Fifty-eight percent of Snap's Q1 2019 advertisers are renewing their spend, according to MediaRadar, signaling long-term adoption.

Read More »

Biogen has seen $19 billion wiped out since a promising drug flopped — and one analyst has a bold idea for how the biotech pioneer can recover

Emma Court | "The company needs to be decisive at this point and make some moves," Mizuho's Salim Syed told Business Insider.

Read More »

JCPenney's suspension of Apple Pay could have broader implications on contactless payments

Rachel Green | JCPenney shed some light on its decision to drop Apple Pay from its retail store and digital platforms.

Read More »